Dermira Inc (DERM) : Acuta Capital Partners added new position in Dermira Inc during the most recent quarter end. The investment management firm now holds 170,000 shares of Dermira Inc which is valued at $5,353,300 , the company said in a statement filed on Aug 15, 2016 with the SEC.Dermira Inc makes up approximately 2.62% of Acuta Capital Partners’s portfolio.
Other Hedge Funds, Including , Balyasny Asset Management boosted its stake in DERM in the latest quarter, The investment management firm added 346,950 additional shares and now holds a total of 612,031 shares of Dermira Inc which is valued at $19,272,856. Dermira Inc makes up approx 0.15% of Balyasny Asset Management’s portfolio. Marshall Wace Llp added DERM to its portfolio by purchasing 41,692 company shares during the most recent quarter which is valued at $1,312,881. Dermira Inc makes up approx 0.01% of Marshall Wace Llp’s portfolio. American Century Companies Inc added DERM to its portfolio by purchasing 46,238 company shares during the most recent quarter which is valued at $1,589,200.
Dermira Inc opened for trading at $30.94 and hit $32.26 on the upside on Thursday, eventually ending the session at $32.22, with a gain of 3.80% or 1.18 points. The heightened volatility saw the trading volume jump to 1,97,402 shares. Company has a market cap of $1,140 M.
Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Wedbush on Jun 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .Company shares were Reiterated by Needham on Jun 2, 2016 to “Buy”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.